The rise of Sildenafil initially sparked a surge for pharma, however recent shifts present a uncertain picture for investors. Generic versions are reducing profits, and ongoing litigation add additional difficulty to https://elainezhco174329.canariblogs.com/the-blue-pill-and-the-pharmaceutical-industry-a-risky-play-56103814